MAGEB4 and non-small cell lung carcinoma: We identified 16 CTAGs (27%) in our RFE set (S3) as being highly discriminatory for survivorship in this distinct cohort of NSCLC patients (SPATA19, SPACA3, TSGA10, TSPY3, LUZP4, TCEA2, CTNNA2, MAGEB2, SPO11, MAGEB4, MAEL, CSAG1, MAGEB5, COX6B2, GAGE2 and TSSK6).